Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts

It's been a sad week for Devyser Diagnostics AB (publ) (STO:DVYSR), who've watched their investment drop 17% to kr108 in the week since the company reported its third-quarter result. It was a pretty negative result overall, with revenues of kr56m missing analyst predictions by 9.5%. Worse, the business reported a statutory loss of kr0.17 per share, a substantial decline on analyst expectations of a profit. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the most recent consensus for Devyser Diagnostics from three analysts is for revenues of kr350.6m in 2026. If met, it would imply a huge 44% increase on its revenue over the past 12 months. Earnings are expected to improve, with Devyser Diagnostics forecast to report a statutory profit of kr2.77 per share. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr366.4m and earnings per share (EPS) of kr2.97 in 2026. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the small dip in earnings per share expectations.

View our latest analysis for Devyser Diagnostics

Despite the cuts to forecast earnings, there was no real change to the kr169 price target, showing that the analysts don't think the changes have a meaningful impact on its intrinsic value. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Devyser Diagnostics, with the most bullish analyst valuing it at kr190 and the most bearish at kr161 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Devyser Diagnostics' rate of growth is expected to accelerate meaningfully, with the forecast 34% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 25% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 11% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Devyser Diagnostics to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also downgraded Devyser Diagnostics' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target held steady at kr169, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Devyser Diagnostics analysts - going out to 2027, and you can see them free on our platform here.

We also provide an overview of the Devyser Diagnostics Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.